GW&K Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $78.2M | Buy |
593,725
+17,077
| +3% | +$2.27M | 0.69% | 33 |
|
|
2025
Q4 | $81.8M | Sell |
576,648
-17,737
| -3% | -$2.57M | 0.71% | 30 |
|
|
2025
Q3 | $83.4M | Sell |
594,385
-17,980
| -3% | -$2.44M | 0.74% | 26 |
|
|
2025
Q2 | $77M | Buy |
612,365
+101,009
| +20% | +$11.6M | 0.69% | 26 |
|
|
2025
Q1 | $56.6M | Sell |
511,356
-2,726
| -0.5% | -$345K | 0.52% | 58 |
|
|
2024
Q4 | $70.2M | Buy |
514,082
+3,993
| +0.8% | +$494K | 0.6% | 47 |
|
|
2024
Q3 | $58.8M | Sell |
510,089
-35,979
| -7% | -$4.93M | 0.5% | 66 |
|
|
2024
Q2 | $75.2M | Buy |
546,068
+18,194
| +3% | +$2.5M | 0.69% | 22 |
|
|
2024
Q1 | $72.8M | Sell |
527,874
-8,088
| -2% | -$1.1M | 0.64% | 36 |
|
|
2023
Q4 | $70.6M | Sell |
535,962
-18,829
| -3% | -$2.17M | 0.66% | 34 |
|
|
2023
Q3 | $62.4M | Sell |
554,791
-19,164
| -3% | -$2.02M | 0.63% | 41 |
|
|
2023
Q2 | $54.1M | Sell |
573,955
-6,842
| -1% | -$669K | 0.51% | 70 |
|
|
2023
Q1 | $58.8M | Buy |
580,797
+6,255
| +1% | +$651K | 0.57% | 57 |
|
|
2022
Q4 | $68.6M | Sell |
574,542
-20,786
| -3% | -$2.43M | 0.7% | 25 |
|
|
2022
Q3 | $63.2M | Sell |
595,328
-21,581
| -3% | -$2.19M | 0.7% | 33 |
|
|
2022
Q2 | $60.1M | Sell |
616,909
-62,530
| -9% | -$5.77M | 0.65% | 37 |
|
|
2022
Q1 | $63.7M | Buy |
679,439
+220,824
| +48% | +$18.7M | 0.57% | 53 |
|
|
2021
Q4 | $39.1M | Buy |
458,615
+14,733
| +3% | +$1.36M | 0.33% | 136 |
|
|
2021
Q3 | $42.6M | Sell |
443,882
-5,476
| -1% | -$517K | 0.38% | 109 |
|
|
2021
Q2 | $43.7M | Buy |
449,358
+8,376
| +2% | +$803K | 0.38% | 111 |
|
|
2021
Q1 | $42.9M | Buy |
440,982
+53,699
| +14% | +$5.63M | 0.4% | 106 |
|
|
2020
Q4 | $37.1M | Sell |
387,283
-1,820
| -0.5% | -$176K | 0.39% | 107 |
|
|
2020
Q3 | $37.4M | Buy |
389,103
+12,137
| +3% | +$1.4M | 0.49% | 71 |
|
|
2020
Q2 | $46M | Buy |
376,966
+3,282
| +0.9% | +$363K | 0.65% | 39 |
|
|
2020
Q1 | $32.3M | Buy |
373,684
+84,421
| +29% | +$8.26M | 0.57% | 55 |
|
|
2019
Q4 | $31.1M | Sell |
289,263
-7,965
| -3% | -$834K | 0.42% | 96 |
|
|
2019
Q3 | $26.8M | Buy |
297,228
+61,645
| +26% | +$5.76M | 0.38% | 117 |
|
|
2019
Q2 | $19.9M | Sell |
235,583
-3,200
| -1% | -$263K | 0.3% | 142 |
|
|
2019
Q1 | $21M | Buy |
238,783
+6,162
| +3% | +$515K | 0.34% | 135 |
|
|
2018
Q4 | $16.6M | Buy |
+232,621
| New | +$22.3M | 0.33% | 136 |
|
|
2018
Q3 | – | Sell |
-82,146
| Closed | -$8.07M | – | 293 |
|
|
2018
Q2 | $8.07M | Sell |
82,146
-350
| -0.4% | -$31.3K | 0.13% | 197 |
|
|
2018
Q1 | $6.84M | Sell |
82,496
-9,033
| -10% | -$763K | 0.12% | 196 |
|
|
2017
Q4 | $7.1M | Buy |
91,529
+9,785
| +12% | +$667K | 0.12% | 189 |
|
|
2017
Q3 | $5.01M | Sell |
81,744
-1,040
| -1% | -$54.9K | 0.08% | 191 |
|
|
2017
Q2 | $3.81M | Sell |
82,784
-1,948
| -2% | -$94.5K | 0.07% | 190 |
|
|
2017
Q1 | $3.67M | Sell |
84,732
-1,555
| -2% | -$66.6K | 0.07% | 189 |
|
|
2016
Q4 | $3.34M | Buy |
86,287
+6,169
| +8% | +$279K | 0.07% | 196 |
|
|
2016
Q3 | $4.06M | Sell |
80,118
-5,470
| -6% | -$272K | 0.08% | 186 |
|
|
2016
Q2 | $3.89M | Buy |
85,588
+18,488
| +28% | +$851K | 0.08% | 188 |
|
|
2016
Q1 | $2.65M | Buy |
+67,100
| New | +$2.66M | 0.06% | 198 |
|
Other funds holding NBIX
VPM
VCM
GW&K Investment Management's NBIX Position: Q1 2026 in Review
GW&K Investment Management increased its Neurocrine Biosciences (NBIX) stake by 3% in Q1 2026, buying an estimated $2.27M and bringing the position to 593,725 shares worth $78.2M. The position accounts for 0.69% of the portfolio, ranked #33.
GW&K Investment Management first reported a position in NBIX in Q1 2016 and has held it in 40 quarters since. The position peaked at $83.4M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- GW&K Investment Management held 593,725 shares of Neurocrine Biosciences worth $78.2M as of Q1 2026.
- GW&K Investment Management bought 17,077 Neurocrine Biosciences shares in Q1 2026, an estimated $2.27M.
- Neurocrine Biosciences made up 0.69% of GW&K Investment Management's portfolio in Q1 2026, its #33 holding.
- GW&K Investment Management first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 40 quarters since.
- GW&K Investment Management's Neurocrine Biosciences position peaked at $83.4M in Q3 2025.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.